Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Podofilox. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 5/20 | 1.00 |
| ▸ | TUBB | P07437 | 5/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 5/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 5/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 5/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 5/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 5/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 1.00 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Podofilox SCHEMBL12377923 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL30947382 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL10005569 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL13663652 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Epipodophyllotoxin SCHEMBL5792464 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL24049951 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL42243 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL13661743 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Podofilox SCHEMBL20807187 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C | |
| Axl-1717 SCHEMBL29358347 | 1.00 | LMNA (1.00) | LMNACYP3A4TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564674-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3561513-A1 | POLYMERIC CARRIERS FOR IMMUNOHISTOCHEMISTRY AND IN SITU HYBRIDIZATION | Ventana Medical Systems, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-2167963-B1 | POLYMERIC CARRIERS FOR IMMUNOHISTOCHEMISTRY AND IN SITU HYBRIDIZATION | VENTANA MED SYST INC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3276349-A1 | HAPTENS, HAPTEN CONJUGATES, COMPOSITIONS THEREOF AND METHOD FOR THEIR PREPARATION AND USE | Ventana Medical Systems, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20120035362-A1 | PHOSPHORAMIDITE DERIVATIVES OF FOLIC ACID | BERRY AND ASSOCIATES, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2012018729-A1 | PHOSPHORAMIDITE DERIVATIVES OF FOLIC ACID | BERRY AND ASSOCIATES, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110244544-A1 | Polymeric carriers for immunohistochemistry and in situ hybridization | VENTANA MEDICAL SYSTEMS, INC. | 2011-10-06 | — | — | US | disclosed |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-7695929-B2 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. | 2008-10-30 | — | — | US | disclosed |
| EP-1362053-B1 | TERMINALLY-BRANCHED POLYMERIC LINKERS AND POLYMERIC CONJUGATES CONTAINING THE SAME | ENZON INC (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1361895-B1 | TERMINALLY-BRANCHED POLYMERIC LINKERS AND POLYMERIC CONJUGATES CONTAINING THE SAME | ENZON INC (US) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | HRH4, CRBN, NCDN | LMNA 3992/4885CYP3A4 71/4885TUBB4A 1174/4885 |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | CRBN, GABBR1, SHBG | LMNA 3003/4885CYP3A4 24/4885TUBB4A 1029/4885 |
| US-20120035362-A1 | PHOSPHORAMIDITE DERIVATIVES OF FOLIC ACID | FOLR1, FOLR2, DHFR | LMNA 2667/4885CYP3A4 3293/4885TUBB4A 2350/4885 |
| US-20110244544-A1 | Polymeric carriers for immunohistochemistry and in situ hybridization | FCGR2A, CD68, CA14 | LMNA 3971/4885CYP3A4 1601/4885TUBB4A 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.